Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Healthcare workers & SARS-CoV-2 infection in India: A case-control investigation in the time of COVID-19

Chatterjee et al., Indian J. Med. Res., June 20, 2020, doi:10.4103/ijmr.IJMR_2234_20
May 2020  
  Source   PDF   All Studies   Meta AnalysisMeta
Case 67% Improvement Relative Risk HCQ for COVID-19  Chatterjee et al.  Prophylaxis Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 455 patients in India Fewer cases with HCQ (p=0.001) Chatterjee et al., Indian J. Med. Res..., May 2020 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments.
4+ doses of HCQ associated with a significant decline in the odds of getting infected, dose-response relationship exists.
risk of case, 66.8% lower, RR 0.33, p < 0.001, treatment 12 of 68 (17.6%), control 206 of 387 (53.2%), NNT 2.8, full course vs. unused.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Chatterjee et al., 28 May 2020, retrospective, India, peer-reviewed, survey, 11 authors.
This PaperHCQAll
{ 'indexed': {'date-parts': [[2024, 4, 6]], 'date-time': '2024-04-06T09:06:05Z', 'timestamp': 1712394365679}, 'reference-count': 38, 'publisher': 'Medknow', 'issue': '5', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2020]]}, 'DOI': '10.4103/ijmr.ijmr_2234_20', 'type': 'journal-article', 'created': {'date-parts': [[2020, 5, 31]], 'date-time': '2020-05-31T08:02:01Z', 'timestamp': 1590912121000}, 'page': '459', 'source': 'Crossref', 'is-referenced-by-count': 114, 'title': 'Healthcare workers &amp; SARS-CoV-2 infection in India: A case-control investigation in the time ' 'of COVID-19', 'prefix': '10.4103', 'volume': '151', 'author': [ {'given': 'Samiran', 'family': 'Panda', 'sequence': 'first', 'affiliation': []}, {'given': 'Pranab', 'family': 'Chatterjee', 'sequence': 'additional', 'affiliation': []}, {'given': 'Tanu', 'family': 'Anand', 'sequence': 'additional', 'affiliation': []}, {'given': 'KhJitenkumar', 'family': 'Singh', 'sequence': 'additional', 'affiliation': []}, {'given': 'Reeta', 'family': 'Rasaily', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ravinder', 'family': 'Singh', 'sequence': 'additional', 'affiliation': []}, {'given': 'Santasabuj', 'family': 'Das', 'sequence': 'additional', 'affiliation': []}, {'given': 'Harpreet', 'family': 'Singh', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ira', 'family': 'Praharaj', 'sequence': 'additional', 'affiliation': []}, {'given': 'RamanR', 'family': 'Gangakhedkar', 'sequence': 'additional', 'affiliation': []}, {'given': 'Balram', 'family': 'Bhargava', 'sequence': 'additional', 'affiliation': []}], 'member': '2581', 'reference': [ { 'key': 'key-10.4103/0971-5916.285520-1', 'first-page': '1320', 'volume-title': 'Community transmission of severe acute respiratory syndrome coronavirus ' '2, Shenzhen, China, 2020', 'author': 'Liu', 'year': '2020', 'journal-title': 'Emerg Infect Dis'}, { 'key': 'key-10.4103/0971-5916.285520-2', 'first-page': '514', 'volume-title': 'A familial cluster of pneumonia associated with the 2019 novel ' 'coronavirus indicating person-to-person transmission: A study of a ' 'family cluster', 'author': 'Chan', 'year': '2020', 'journal-title': 'Lancet'}, { 'key': 'key-10.4103/0971-5916.285520-3', 'first-page': '1199', 'volume-title': 'Early transmission dynamics in Wuhan, China, of novel ' 'coronavirus-infected pneumonia', 'author': 'Li', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': 'key-10.4103/0971-5916.285520-4', 'first-page': '147', 'volume-title': 'The 2019 novel coronavirus disease (COVID-19) pandemic: A review of the ' 'current evidence', 'author': 'Chatterjee', 'year': '2020', 'journal-title': 'Indian J Med Res'}, { 'key': 'key-10.4103/0971-5916.285520-5', 'first-page': 'e1', 'volume-title': 'Rapid asymptomatic transmission of COVID-19 during the incubation period ' 'demonstrating strong infectivity in a cluster of youngsters aged 16-23 ' 'years outside Wuhan and characteristics of young patients with COVID-19: ' 'A prospective contact-tracing study', 'author': 'Huang', 'year': '2020', 'journal-title': 'J Infect'}, { 'key': 'key-10.4103/0971-5916.285520-6', 'doi-asserted-by': 'crossref', 'unstructured': 'Nguyen LH, Drew DA, Joshi AD, Guo C-G, Ma W, Mehta RS, et al. Risk of ' 'COVID-19 among frontline healthcare workers and the general community: A ' 'prospective cohort study. medRxiv 2020. doi: ' '', 'DOI': '10.1101/2020.04.29.20084111'}, { 'key': 'key-10.4103/0971-5916.285520-7', 'doi-asserted-by': 'crossref', 'unstructured': 'Lewnard JA, Lo NC. Scientific and ethical basis for social-distancing ' 'interventions against COVID-19. Lancet Infect Dis 2020. doi: ' '10.1016/S1473-3099(20)30190-0.', 'DOI': '10.1016/S1473-3099(20)30190-0'}, { 'key': 'key-10.4103/0971-5916.285520-8', 'doi-asserted-by': 'crossref', 'unstructured': 'Prather KA, Wang CC, Schooley RT. Reducing transmission of SARS-CoV-2. ' 'Science 2020. pii: eabc6197.', 'DOI': '10.1126/science.abc6197'}, { 'key': 'key-10.4103/0971-5916.285520-9', 'unstructured': 'World Health Organization. Coronavirus disease (COVID-19) advice for the ' 'public. Geneva: WHO; 2020.'}, { 'key': 'key-10.4103/0971-5916.285520-10', 'first-page': '922', 'volume-title': 'COVID-19: Protecting health-care workers', 'author': 'The', 'year': '2020', 'journal-title': 'Lancet'}, { 'key': 'key-10.4103/0971-5916.285520-11', 'first-page': 'CD011621', 'volume-title': 'Personal protective equipment for preventing highly infectious diseases ' 'due to exposure to contaminated body fluids in healthcare staff', 'author': 'Verbeek', 'year': '2016', 'journal-title': 'Cochrane Database Syst Rev'}, { 'key': 'key-10.4103/0971-5916.285520-12', 'first-page': '1406', 'volume-title': 'Presumed asymptomatic carrier transmission of COVID-19', 'author': 'Bai', 'year': '2020', 'journal-title': 'JAMA'}, { 'key': 'key-10.4103/0971-5916.285520-13', 'unstructured': 'World Health Organization. Novel coronavirus (2019-nCoV) - Situation ' 'Report - 2; January 22, 2020. Geneva: WHO; 2020.'}, { 'key': 'key-10.4103/0971-5916.285520-14', 'first-page': '1353', 'volume-title': 'Epidemiology and cause of severe acute respiratory syndrome (SARS) in ' "Guangdong, People's Republic of China, in February, 2003", 'author': 'Zhong', 'year': '2003', 'journal-title': 'Lancet'}, { 'key': 'key-10.4103/0971-5916.285520-15', 'first-page': '35', 'volume-title': 'Middle East respiratory syndrome coronavirus (MERS-CoV): A review', 'author': 'Ramadan', 'year': '2019', 'journal-title': 'Germs'}, { 'key': 'key-10.4103/0971-5916.285520-16', 'first-page': '101735', 'volume-title': 'Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and ' 'other viral infections: A narrative review?', 'author': 'Hashem', 'year': '2020', 'journal-title': 'Travel Med Infect Dis'}, { 'key': 'key-10.4103/0971-5916.285520-17', 'first-page': '16', 'volume-title': 'Hydroxychloroquine, a less toxic derivative of chloroquine, is effective ' 'in inhibiting SARS-CoV-2 infection in vitro', 'author': 'Liu', 'year': '2020', 'journal-title': 'Cell Discov'}, { 'key': 'key-10.4103/0971-5916.285520-18', 'first-page': 'e00293', 'volume-title': 'Targeting endosomal acidification by chloroquine analogs as a promising ' 'strategy for the treatment of emerging viral diseases', 'author': 'Al-Bari', 'year': '2017', 'journal-title': 'Pharmacol Res Perspect'}, { 'key': 'key-10.4103/0971-5916.285520-19', 'first-page': '69', 'volume-title': 'Chloroquine is a potent inhibitor of SARS coronavirus infection and ' 'spread', 'author': 'Vincent', 'year': '2005', 'journal-title': 'Virol J'}, { 'key': 'key-10.4103/0971-5916.285520-20', 'unstructured': 'National Task Force for COVID-19 in India. Recommendation for empiric ' 'use of hydroxychloroquine for prophylaxis of SARS-CoV-2 infection; 2020. ' 'Available from: ' ' ' 'nasprophylaxisforSARSCoV2infection.pdf, accessed on May 25, 2020.'}, { 'key': 'key-10.4103/0971-5916.285520-21', 'doi-asserted-by': 'crossref', 'unstructured': 'Lee SH, Son H, Peck KR. Can post-exposure prophylaxis for COVID-19 be ' 'considered as an outbreak response strategy in long-term care hospitals? ' 'Int J Antimicrob Agents 2020. doi: 10.1016/j.ijantimicag.2020.105988.', 'DOI': '10.1016/j.ijantimicag.2020.105988'}, { 'key': 'key-10.4103/0971-5916.285520-22', 'first-page': '30296', 'volume-title': 'Chloroquine or hydroxychloroquine for prophylaxis of COVID-19.Lancet ' 'Infect Dis 2020', 'author': 'Principi', 'year': '1473', 'journal-title': 'pii: S'}, { 'key': 'key-10.4103/0971-5916.285520-23', 'first-page': '1157', 'volume-title': 'Power calculations for matched case-control studies', 'author': 'Dupont', 'year': '1988', 'journal-title': 'Biometrics'}, { 'key': 'key-10.4103/0971-5916.285520-24', 'unstructured': 'Hintze J. PASS 11. NCSS, LLC. Kaysville, Utah, USA: NCSS; 2011. ' 'Available from:">, accessed on ' 'May 25, 2020.'}, { 'key': 'key-10.4103/0971-5916.285520-25', 'first-page': 'i969', 'volume-title': 'Analysis of matched case-control studies', 'author': 'Pearce', 'year': '2016', 'journal-title': 'BMJ'}, { 'key': 'key-10.4103/0971-5916.285520-26', 'first-page': '200', 'volume-title': 'Lessons from the Ebola outbreak: Action items for emerging infectious ' 'disease preparedness and response', 'author': 'Jacobsen', 'year': '2016', 'journal-title': 'Ecohealth'}, { 'key': 'key-10.4103/0971-5916.285520-27', 'first-page': '1867', 'volume-title': 'Outbreak investigation of Nipah virus disease in Kerala, India, 2018', 'author': 'Arunkumar', 'year': '2019', 'journal-title': 'J Infect Dis'}, { 'key': 'key-10.4103/0971-5916.285520-28', 'doi-asserted-by': 'crossref', 'unstructured': 'Zhou D, Dai SM, Tong Q. COVID-19: A recommendation to examine the effect ' 'of hydroxychloroquine in preventing infection and progression. J ' 'Antimicrob Chemother 2020. doi:10.1093/jac/dkaa114.', 'DOI': '10.1093/jac/dkaa114'}, { 'key': 'key-10.4103/0971-5916.285520-29', 'first-page': '771', 'volume-title': 'Bioavailability of hydroxychloroquine tablets in healthy volunteers', 'author': 'Tett', 'year': '1989', 'journal-title': 'Br J Clin Pharmacol'}, { 'key': 'key-10.4103/0971-5916.285520-30', 'doi-asserted-by': 'crossref', 'unstructured': 'Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or ' 'chloroquine with or without a macrolide for treatment of COVID-19: A ' 'multinational registry analysis. Lancet 2020; S0140-6736(20)31180-6.', 'DOI': '10.1016/S0140-6736(20)31180-6'}, { 'key': 'key-10.4103/0971-5916.285520-31', 'first-page': '1033', 'volume-title': 'COVID-19: Consider cytokine storm syndromes and immunosuppression', 'author': 'Mehta', 'year': '2020', 'journal-title': 'Lancet'}, { 'key': 'key-10.4103/0971-5916.285520-32', 'first-page': 'e639', 'volume-title': 'Use of antiviral drugs to reduce COVID-19 transmission', 'author': 'Mitjà', 'year': '2020', 'journal-title': 'Lancet Glob Health'}, { 'key': 'key-10.4103/0971-5916.285520-33', 'doi-asserted-by': 'crossref', 'unstructured': 'Bellizzi S, Fiamma M, Arru L, Farina G, Manca A. COVID-19: The daunting ' 'experience of healthcare workers in Sardinia, Italy. Infect Control Hosp ' 'Epidemiol 2020. doi:10.1017/ice.2020.149.', 'DOI': '10.1017/ice.2020.149'}, { 'key': 'key-10.4103/0971-5916.285520-34', 'doi-asserted-by': 'crossref', 'unstructured': 'Barrett ES, Horton DB, Roy J, Gennaro ML, Brooks A, Tischfield J, et al. ' 'Prevalence of SARS-CoV-2 infection in previously undiagnosed health care ' 'workers at the onset of the U.S. COVID-19 epidemic. ' 'medRxiv:2020.04.20.20072470; 2020. doi:10.1101/2020.04.20.20072470.', 'DOI': '10.1101/2020.04.20.20072470'}, { 'key': 'key-10.4103/0971-5916.285520-35', 'first-page': 'e251', 'volume-title': 'The resilience of the Spanish health system against the COVID-19 ' 'pandemic', 'author': 'Legido-Quigley', 'year': '2020', 'journal-title': 'Lancet Public Health'}, { 'key': 'key-10.4103/0971-5916.285520-36', 'first-page': '400', 'volume-title': 'Condoms and seat belts: The parallels and the lessons', 'author': 'Richens', 'year': '2000', 'journal-title': 'Lancet'}, { 'key': 'key-10.4103/0971-5916.285520-37', 'unstructured': 'Adams J. Risk, 1st ed. London: Routledge, Taylor & Fransis Group; 1995. ' 'Available from: ' '">, ' 'accessed on May 28, 2020.'}, { 'key': 'key-10.4103/0971-5916.285520-38', 'unstructured': 'Wilde GJS. Target risk: Dealing with the danger of death, disease and ' 'damage in everyday decisions. Toronto, ON, Canada: Castor & Columba; ' '1994.'}], 'container-title': 'Indian Journal of Medical Research', 'original-title': [], 'language': 'en', 'deposited': { 'date-parts': [[2021, 12, 20]], 'date-time': '2021-12-20T13:44:37Z', 'timestamp': 1640007877000}, 'score': 1, 'resource': { 'primary': { 'URL': ''}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020]]}, 'references-count': 38, 'journal-issue': {'issue': '5', 'published-print': {'date-parts': [[2020]]}}, 'alternative-id': ['285520'], 'URL': '', 'relation': {}, 'ISSN': ['0971-5916'], 'subject': ['General Biochemistry, Genetics and Molecular Biology', 'General Medicine'], 'container-title-short': 'Indian J Med Res', 'published': {'date-parts': [[2020]]}}
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop